Taken together, activation of the PI3K/Akt/mTOR pathway plays a central role in breast cancer, and blocking of this pathway is an attractive treatment target, especially in endocrine-resistant ER-positive breast cancer. This evidence concerns the gene AKT1 and breast cancer.